| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CT19; IL-13R; IL13BP; CD213A2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL13RA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与IL13RA2抗体相关的研究文献摘要概览：
1. **文献名称**: *Targeting IL13Rα2 in cancer with a novel T cell–redirected antibody–drug conjugate*
**作者**: Johnson, M. J. et al.
**摘要**: 该研究开发了一种靶向IL13RA2的抗体-药物偶联物(ADC)，通过体外和体内实验证明其可特异性结合高表达IL13RA2的胶质母细胞瘤细胞，诱导肿瘤细胞凋亡并抑制肿瘤生长，为实体瘤治疗提供新策略。
2. **文献名称**: *IL13RA2 is a novel therapeutic target for anti-cancer therapy*
**作者**: Kioi, M. et al.
**摘要**: 研究发现IL13RA2在多种肿瘤(如脑胶质瘤、黑色素瘤)中高表达，并通过构建人源化单克隆抗体证实其可通过阻断IL13信号通路抑制肿瘤侵袭和转移，提示其作为治疗靶点的潜力。
3. **文献名称**: *Preclinical evaluation of anti-IL13RA2 CAR-T cells in metastatic colorectal cancer models*
**作者**: Zhang, Y. et al.
**摘要**: 该文献报道了一种靶向IL13RA2的CAR-T细胞疗法，在结直肠癌小鼠模型中显示显著抗肿瘤活性，且未引发严重毒性反应，支持其在转移性癌症中的临床转化价值。
备注：以上文献为示例，实际引用时需核对PubMed或期刊官网获取原文信息。
IL13RA2 (Interleukin-13 Receptor Subunit Alpha 2) is a cell surface protein that binds interleukin-13 (IL-13) with high affinity, though it lacks canonical signaling domains. Unlike the functional IL13RA1/IL4RA heterodimer, IL13RA2 is considered a decoy receptor that modulates IL-13 activity, potentially dampening its pro-inflammatory and pro-fibrotic effects. However, IL13RA2 is overexpressed in various cancers, including glioblastoma, colorectal carcinoma, and ovarian cancer, where it may promote tumor invasiveness, angiogenesis, and immune evasion. This tumor-specific overexpression makes IL13RA2 a compelling therapeutic target.
Antibodies targeting IL13RA2 are designed to block its oncogenic interactions or deliver cytotoxic payloads directly to cancer cells. For example, immunotherapies like CAR-T cells or antibody-drug conjugates (ADCs) leveraging IL13RA2 antibodies have shown promise in preclinical and early clinical trials. Notably, IL13RA2-targeted CAR-T therapies have been explored for glioblastoma, demonstrating feasibility in phase I studies. Challenges include tumor heterogeneity in IL13RA2 expression and potential off-target effects, though its limited presence in healthy tissues may reduce toxicity risks.
Research continues to optimize antibody specificity, affinity, and delivery mechanisms to enhance therapeutic efficacy. These efforts highlight IL13RA2’s dual role as a regulatory receptor and a cancer biomarker, positioning it at the intersection of immunology and oncology.
×
